Loading...

SNF

SNY

SANOFI

(SNY)

2025 6-K

Summary

Summary

Sanofi Updates

26 Sep '25

Sanofi Updates

22 Sep '25

Sanofi Announcements

17 Sep '25

Study Success

4 Sep '25

FDA Approval

3 Sep '25

Orphan Designation

29 Aug '25

Acquisition Completed

7 Aug '25

Filing Summary

31 Jul '25

Q2 Sales Growth

31 Jul '25

Sanofi Updates

31 Jul '25

Sanofi Updates

22 Jul '25

Sanofi Acquisition

18 Jul '25

Drug Designation Update

2 Jul '25

New Drug Approvals

24 Jun '25

Bond Issue Announcement

18 Jun '25

Global Shipping Update

17 Jun '25

Sanofi Updates

6 Jun '25

Sanofi Press Release

2 Jun '25

Sanofi Updates

30 May '25

Sanofi Acquisition

22 May '25

Annual Meeting Notice

5 May '25

Opella Transaction

30 Apr '25

Strong Q1 Performance

24 Apr '25

New Therapy Approval

22 Apr '25

Respiratory Pipeline Update

16 Apr '25

MS Data Release

10 Apr '25

Orphan Drug Designation

4 Apr '25

Regulatory Filings

2 Apr '25

Regulatory Submissions

26 Mar '25

Sanofi Acquisition

20 Mar '25

Positive Data Release

10 Mar '25

Bond Issue Announcement

6 Mar '25

Product Approvals

28 Feb '25

FDA Review Accepted

20 Feb '25

Vaccine Study Update

13 Feb '25

Share Buyback Agreement

7 Feb '25

Recent Developments

3 Feb '25

Q4 Sales Growth

30 Jan '25

Sanofi Updates

24 Jan '25

Sanofi Updates

14 Jan '25

Sanofi Board Update

23 Dec '24

FDA Breakthrough Designation

20 Dec '24

Sanofi Updates

13 Dec '24

Regulatory Updates

18 Nov '24

Dupixent Approval

7 Nov '24

Positive Data Announcement

31 Oct '24

Q3 Sales Growth

25 Oct '24

Partnership Announcements

21 Oct '24

Sanofi Updates

11 Oct '24

Dupixent Approval

2 Oct '24

Sanofi Updates

24 Sep '24

Positive Developments

13 Sep '24

Tolebrutinib Success

3 Sep '24

Treatment Improvement

13 Aug '24

Strong Q2 Performance

25 Jul '24

Q2 Financial Report

25 Jul '24

New Treatments Approved

23 Jul '24

Sanofi Updates

2 Jul '24

FDA Updates

11 Jun '24

Sanofi 6-K Filing

30 May '24

Sanofi Updates

28 May '24

Sanofi Updates

2 May '24

Q1 Sales Growth

25 Apr '24

New Clinical Results

20 Mar '24

February Updates

27 Feb '24

Employee Support Program

15 Feb '24

Sanofi Updates

2 Feb '24

Sales Growth Report

1 Feb '24

Press Release Update

23 Jan '24

Management Change

17 Jan '24

External Links:

SEC

In September 2025, Sanofi reported several significant developments: Tzield was approved in China for type 1 diabetes, SAR402663 received fast track designation in the US, and brivekimig showed positive results in a phase 2a study for hidradenitis suppurativa. These events are aimed at improving treatment options for patients.

AI Assistant

SANOFI

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.